Registered title, quoted from ClinicalTrials.gov
Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Tianjin Medical University Cancer Institute & Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07560488, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Normal thyroid function defined as thyroid-stimulating hormone (TSH) within normal limits. Subjects with abnormal baseline TSH but normal total T3 (or FT3) and FT4 are also eligible;
Inclusion criterion 17
Symptomatic congestive heart failure (NYHA Class II-IV); symptomatic or poorly controlled arrhythmia; congenital long QT syndrome or QTcF >500 ms at screening;
Exclusion criterion 16
All subjects (male or female) of reproductive potential must use a highly effective contraceptive method with an annual failure rate < 1% throughout treatment and for 120 days after the last dose of immunotherapy or 180 days after the last dose of chemotherapy, whichever is longer.
Inclusion criterion 20
Prior treatment with anti-PD-1, anti-PD-L1/L2, anti-CTLA-4 antibodies, or other immune checkpoint inhibitors;
Exclusion criterion 30
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
Inclusion criterion 7
Absolute neutrophil count (ANC) ≥ 1.5×10⁹/L without granulocyte colony-stimulating factor support within 14 days;
Inclusion criterion 10
Platelet count ≥ 80×10⁹/L without transfusion within 14 days;
Inclusion criterion 11
Hemoglobin > 9 g/dL without transfusion or erythropoietin within 14 days;
Inclusion criterion 12
Total bilirubin ≤ 1.5×upper limit of normal (ULN); or total bilirubin > ULN with direct bilirubin ≤ ULN;
Inclusion criterion 13
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3×ULN;
Inclusion criterion 14
Serum creatinine ≤ 1.5×ULN and creatinine clearance (calculated by Cockcroft-Gault formula) ≥ 60 mL/min;
Inclusion criterion 15
Autoimmune hepatitis (requiring liver biopsy confirmation);
Exclusion criterion 5
Acute or chronic active hepatitis B or C infection:HBV DNA >2000 IU/mL or 10⁴ copies/mL;HCV RNA >10³ copies/mL;coinfection with HBsAg and anti-HCV antibody;
Exclusion criterion 20
Active tuberculosis (TB), ongoing anti-TB treatment, or anti-TB treatment within 1 year before first dose;
Exclusion criterion 21
Human immunodeficiency virus (HIV) infection (positive HIV 1/2 antibody) or active syphilis;
Exclusion criterion 22
Diagnosis of another malignancy within 5 years before first dose, except for radically treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ.For other malignancies diagnosed >5 years before enrollment, pathological or cytological confirmation of recurrent/metastatic lesions is required;
Exclusion criterion 29
Female subjects who are pregnant or breastfeeding;
Exclusion criterion 33
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07560488, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Written informed consent must be signed prior to initiation of any study-related procedures;
- Age ≥ 18 years, and ≤75 years, regardless of gender;
- Clinically diagnosed or histologically/cytologically confirmed hepatocellular carcinoma (HCC) according to the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition);
- No prior anti-tumor therapy for HCC before study treatment
- Unresectable locally advanced or advanced HCC (CNLC Stage IIa-IIIb).
- Expected overall survival > 6 months.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- Child-Pugh score class A or B
- Adequate organ function defined by the following laboratory parameters:
- Absolute neutrophil count (ANC) ≥ 1.5×10⁹/L without granulocyte colony-stimulating factor support within 14 days;
- Platelet count ≥ 80×10⁹/L without transfusion within 14 days;
- Hemoglobin > 9 g/dL without transfusion or erythropoietin within 14 days;
- Total bilirubin ≤ 1.5×upper limit of normal (ULN); or total bilirubin > ULN with direct bilirubin ≤ ULN;
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3×ULN;
- Serum creatinine ≤ 1.5×ULN and creatinine clearance (calculated by Cockcroft-Gault formula) ≥ 60 mL/min;
- Adequate coagulation function defined as international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5×ULN;
- Normal thyroid function defined as thyroid-stimulating hormone (TSH) within normal limits. Subjects with abnormal baseline TSH but normal total T3 (or FT3) and FT4 are also eligible;
- Myocardial enzymes within normal limits; isolated laboratory abnormalities deemed clinically insignificant by the investigator are permitted.
- Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 3 days before the first dose of study drug (Day 1 of Cycle 1). A blood pregnancy test is required if the urine test is inconclusive; They must agree to use adequate contraception during the study period and for 8 weeks after the last dose of study drug;
- All subjects (male or female) of reproductive potential must use a highly effective contraceptive method with an annual failure rate < 1% throughout treatment and for 120 days after the last dose of immunotherapy or 180 days after the last dose of chemotherapy, whichever is longer.
Exclusion Criteria:
- Target disease exceptions:
- Fibrolamellar HCC, sarcomatoid HCC, or combined hepatocellular-cholangiocarcinoma.
- Recurrent HCC.
- Clinically diagnosed hepatic encephalopathy within the most recent 6 months.
- Autoimmune hepatitis (requiring liver biopsy confirmation);
- History of organ transplantation or history of hepatic encephalopathy;
- Diffuse hepatocellular carcinoma;
- Symptomatic pleural effusion, ascites, or pericardial effusion requiring drainage;
- History of any renal disease or nephrotic syndrome.
- Variceal bleeding (esophageal or gastric varices) due to portal hypertension within the past 6 months;severe (Grade 3) varices on endoscopy within 3 months before first dose;evidence of portal hypertension (e.g., splenomegaly >10 cm in longest diameter with platelets <100×10⁹/L on imaging) with high bleeding risk as assessed by the investigator;
- Arterial or venous thromboembolic events within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other severe thromboembolism.Excluded are catheter-related or port-related thrombosis or superficial venous thrombosis that is stable with standard anticoagulation;
- Severe bleeding tendency or coagulopathy, or ongoing thrombolytic therapy;
- Prophylactic low-molecular-weight heparin (e.g., enoxaparin 40 mg daily) is permitted; vitamin K antagonists (e.g., warfarin) are excluded;
- Long-term use of anti-platelet agents including aspirin, dipyridamole, clopidogrel, or other similar medications;
- Uncontrolled hypertension despite optimal medical management (systolic BP >140 mmHg or diastolic BP >90 mmHg); history of hypertensive crisis or hypertensive encephalopathy;
- Symptomatic congestive heart failure (NYHA Class II-IV); symptomatic or poorly controlled arrhythmia; congenital long QT syndrome or QTcF >500 ms at screening;
- History of gastrointestinal perforation and/or fistula within the past 6 months; history of bowel obstruction (including partial obstruction requiring parenteral nutrition); extensive bowel resection, Crohn's disease, ulcerative colitis, or chronic diarrhea;
- Major surgical procedure (cranial, thoracic, or abdominal) within 4 weeks before first dose, or non-healing wounds, ulcers, or fractures.Core needle biopsy or minor surgery within 7 days before first dose is excluded, except for venous catheter placement for intravenous access;
- History of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-induced pneumonitis, or severe pulmonary dysfunction;
- Acute or chronic active hepatitis B or C infection:HBV DNA >2000 IU/mL or 10⁴ copies/mL;HCV RNA >10³ copies/mL;coinfection with HBsAg and anti-HCV antibody;
- Active tuberculosis (TB), ongoing anti-TB treatment, or anti-TB treatment within 1 year before first dose;
- Human immunodeficiency virus (HIV) infection (positive HIV 1/2 antibody) or active syphilis;
- Active or poorly controlled severe infection; severe infection requiring hospitalization (including sepsis, bacteremia, or severe pneumonia) within 4 weeks before first dose;
- Active autoimmune disease requiring systemic therapy (e.g., disease-modifying agents, corticosteroids, or immunosuppressants) within 2 years before first dose.Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroids for adrenal/pituitary insufficiency) is permitted.History of primary immunodeficiency.Subjects with isolated positive autoimmune antibodies will be evaluated at the investigator's discretion;
- Systemic immunosuppressive drugs within 4 weeks before first dose, excluding topical, inhaled, or intranasal corticosteroids or physiological systemic corticosteroids (≤10 mg/day prednisone or equivalent).Temporary corticosteroids for acute dyspnea in asthma or COPD are permitted;
- Live attenuated vaccine within 4 weeks before first dose or planned use during the study period;
- Chinese herbal medicine with anti-tumor indications, or immunomodulatory agents (including thymosin, interferon, interleukin) within 2 weeks before first dose, except for local administration for pleural effusion or ascites;
- Uncontrolled or irreversible metabolic disorders, other acute or chronic non-malignant organ diseases, systemic illnesses, or paraneoplastic syndromes that may increase medical risk or confound survival assessment;
- Diagnosis of another malignancy within 5 years before first dose, except for radically treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ.For other malignancies diagnosed >5 years before enrollment, pathological or cytological confirmation of recurrent/metastatic lesions is required;
- Prior treatment with anti-PD-1, anti-PD-L1/L2, anti-CTLA-4 antibodies, or other immune checkpoint inhibitors;
- Known hypersensitivity to sintilimab, bevacizumab, ipilimumab N01 or their excipients, or severe hypersensitivity to other monoclonal antibodies;
- Participation in another interventional clinical trial within 4 weeks before first dose;
- Female subjects who are pregnant or breastfeeding;
- Any other acute or chronic diseases, psychiatric disorders, or abnormal laboratory values that may increase risks associated with study participation or study drug administration, or interfere with the interpretation of study results, and that, in the investigator's judgment, render the patient ineligible for participation in this study.
Quoted from ClinicalTrials.gov, NCT07560488, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07560488, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.